"The authors present a meta-analysis of the effects of statin treatment on all-cause mortality in intermediate to high-risk patients without prevalent CVD. This investigation is by far the largest analysis of statin therapy in a purely primary prevention setting. Although the cohorts varied considerably with respect to the recruitment strategy, mean age and cardiovascular risk profile, the authors observed a consistent null result (for statin benefit) independent of mean baseline LDL concentration and mean LDL-C reduction in the treatment arm and without evidence of relevant heterogeneity across cohorts."